Osborne CK - Search Results

1

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.

Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Anurag M, et al. Among authors: osborne ck. Cancer Discov. 2022 Nov 2;12(11):2586-2605. doi: 10.1158/2159-8290.CD-22-0200. Cancer Discov. 2022. PMID: 36001024 Free PMC article.

2

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O'Connell P. Chang JC, et al. Among authors: osborne ck. J Clin Oncol. 2005 Feb 20;23(6):1169-77. doi: 10.1200/JCO.2005.03.156. J Clin Oncol. 2005. PMID: 15718313

3

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.

Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Schiff R, et al. Among authors: osborne ck. Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:10-20. doi: 10.1007/s00280-005-0108-2. Cancer Chemother Pharmacol. 2005. PMID: 16273359 Review.

4

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Massarweh S, et al. Among authors: osborne ck. Cancer Res. 2006 Aug 15;66(16):8266-73. doi: 10.1158/0008-5472.CAN-05-4045. Cancer Res. 2006. PMID: 16912207

5

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. Arpino G, et al. Among authors: osborne ck. J Natl Cancer Inst. 2007 May 2;99(9):694-705. doi: 10.1093/jnci/djk151. J Natl Cancer Inst. 2007. PMID: 17470737

6

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Massarweh S, et al. Among authors: osborne ck. Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707. Cancer Res. 2008. PMID: 18245484

7

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Li X, et al. Among authors: osborne ck. J Natl Cancer Inst. 2008 May 7;100(9):672-9. doi: 10.1093/jnci/djn123. Epub 2008 Apr 29. J Natl Cancer Inst. 2008. PMID: 18445819

8

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.

Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM. Rimawi MF, et al. Among authors: osborne ck. Cancer. 2010 Mar 1;116(5):1234-42. doi: 10.1002/cncr.24816. Cancer. 2010. PMID: 20082448 Free PMC article.

9

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.

Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC. Rodriguez AA, et al. Among authors: osborne ck. Breast Cancer Res Treat. 2010 Aug;123(1):189-96. doi: 10.1007/s10549-010-0983-z. Epub 2010 Jun 26. Breast Cancer Res Treat. 2010. PMID: 20582464

10

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. Dave B, et al. Among authors: osborne ck. J Clin Oncol. 2011 Jan 10;29(2):166-73. doi: 10.1200/JCO.2009.27.7814. Epub 2010 Dec 6. J Clin Oncol. 2011. PMID: 21135276 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

372 results

Search Page